Rate-Dependence of Antiarrhythmic Drug Action

Singh, Bramah N.; Wadhani, Nitin; Sarma, J. S. M.

doi:10.1177/107424840200700401

Cited by 2 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CL dependence is a characteristic property of antiarrhythmic drugs belonging to the Vaughan William classes I and III. 25 Interestingly, as typical class I, PC’s effect on V max is most marked at fast heart rates and nearly nonexistent at slow or physiological heart rates. PC also exerts a reverse CL dependence regard to the AP lengthening (Figure 3).…”

Section: Discussionmentioning

confidence: 91%

“…Typical class III drugs exhibit reverse rate dependence regarding APD lengthening. 25 This reverse rate dependence of the APD lengthening is undesirable because it minimizes drug effects on repolarization during VAs and enhances their proarrhythmic potential at normal rates. 25 Unlike typical class III drugs, PC presents atypical class III properties with the prolongation of the APD most marked at both high and slow heart rates that could be explained by the associated class I effects.…”

Section: Discussionmentioning

confidence: 99%

“…25 This reverse rate dependence of the APD lengthening is undesirable because it minimizes drug effects on repolarization during VAs and enhances their proarrhythmic potential at normal rates. 25 Unlike typical class III drugs, PC presents atypical class III properties with the prolongation of the APD most marked at both high and slow heart rates that could be explained by the associated class I effects. Finally, via multichannel properties, PC exerts classes III and I effects at high heart rates, class III effects at slow heart rates, and neutral effect at physiological heart rates.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Electrophysiological and Antiarrhythmic Properties of Potassium Canrenoate During Myocardial Ischemia–Reperfusion

Alexandre

Beygui

Puddu

et al. 2014

J Cardiovasc Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Electrophysiological and Antiarrhythmic Properties of Potassium Canrenoate During Myocardial Ischemia–Reperfusion

Alexandre

Beygui

Puddu

et al. 2014

J Cardiovasc Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…See text for details. From Singh et al (49). Stimulation CL, msec associated with a parallel shift (ie, ERP increases in a parallel fashion over a wide range of frequencies), as noted in the case of azimilide and ambasilide (46).…”

Section: Rate-dependent Effect Of Antifibrillatory Drugsmentioning

confidence: 95%

“…How antiarrhythmic mechanisms continue to be classified is briefly discussed, since they still have utility in the choice of antifibrillatory agents in clinical practice and appear to have been the basis for the synthesis of newer compounds. A major focus is on atrial selectivity (49), which is of critical importance in the use of these agents for controlling AF and flutter.…”

Section: Mechanisms Of Actions Of Antiarrhythmic Drugs: Relevance To mentioning

confidence: 99%

Atrial Fibrillation: Epidemiologic Considerations and Rationale for Conversion and Maintenance of Sinus Rhythm

Singh

2003

J Cardiovasc Pharmacol Ther

Self Cite

View full text Add to dashboard Cite

Atrial fibrillation is now the most common cardiac arrhythmia for which a patient is hospitalized. Clinically, it presents in a form that is paroxysmal, persistent, or permanent and may be symptomatic or asymptomatic, occurring in the setting of either no cardiac disease ("lone atrial fibrillation") or, most often, in association with an underlying disease. Atrial fibrillation is associated with a 2-fold increase in mortality and, in the United States alone, causes over 75,000 cases of stroke per year. The annual prevalence of stroke is 5% to 7%, but the use of adequate anticoagulation can reduce this to less than 1%. Atrial fibrillation is a disorder of the elderly, with almost equal prevalence in men and women. In the United States, 80% of atrial fibrillation occurs in patients over the age of 65 years, and its prevalence tracks that of heart failure, which may be the cause, as well as the result, of the arrhythmia. Both conditions are increasing in epidemic proportions in the aging population. The most common causes of atrial fibrillation are hypertensive heart disease, coronary artery disease, and heart failure with a miscellany of lesser conditions, with about 10% lacking structural heart disease. Unlike other supraventricular arrhythmias, cure by the use of catheter ablation and surgical techniques has not been a reality except in a relatively small number of cases. However, restoration and maintenance of sinus rhythm remain the initial goal of therapy for most patients. Pharmacologic approaches remain the mainstay of therapy for rate control and anticoagulation as well as for maintenance of sinus rhythm following pharmacological or electrical conversion. The changing epidemiology of atrial fibrillation is highlighted, with the focus on its conversion by the use of newer and novel antifibrillatory agents relative to the mechanisms of the arrhythmia, to restore the stability of sinus rhythm.

show abstract

Rate-Dependence of Antiarrhythmic Drug Action

Cited by 2 publications

References 18 publications

Electrophysiological and Antiarrhythmic Properties of Potassium Canrenoate During Myocardial Ischemia–Reperfusion

Electrophysiological and Antiarrhythmic Properties of Potassium Canrenoate During Myocardial Ischemia–Reperfusion

Atrial Fibrillation: Epidemiologic Considerations and Rationale for Conversion and Maintenance of Sinus Rhythm

Contact Info

Product

Resources

About